Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan
– GSK’s rotavirus vaccine approved for use in babies for the prevention of rotavirus gastroenteritis – Lamotrigine becomes the first treatment to be ap...
Read more -
GSK welcomes external scientists to diseases of the developing world research campus
GSK will provide support, expertise and facilities as part of our open innovation strategy to spur global collaboration in research
Read more -
GSK statement on University of East Anglia study examining health impacts of anticholinergic medicines for over 65s
Research led by the University of East Anglia has been published in the Journal of the American Geriatrics Society i examining the long term health impacts of anticholinergic me...
Read more -
GSK statement on agreements with State Attorneys General on former Cidra manufacturing facility
GlaxoSmithKline (GSK) has agreed to pay $40.75 million, which will be divided among 37 states and the District of Columbia, as part of an agreement reached related to events dur...
Read more -
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
GlaxoSmithKline (GSK) announced today that it has entered into an agreement to acquire the remaining 51% equity interest of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd (Ne...
Read more -
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga&...
Read more -
Millions of children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease under new offer made by GSK to the GAVI Alliance
GSK today announced that it has made a new offer to supply its rotavirus vaccine, Rotarix, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices.
Read more -
GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas
Results of the PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) study presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statis...
Read more -
GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD
GSK and Theravance, Inc. today announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with COPD.
Read more -
GSK forms partnership with three leading NGOs to address shortage of frontline healthcare workers in Least Developed Countries LDCs
- Agreements signed with AMREF, CARE International UK and Save the Children as part of commitment to reinvest 20% of profits in LDCs
Read more -
GlaxoSmithKline and Human Genome Sciences receive positive opinion in Europe from the CHMP for Benlysta® belimumab
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (C...
Read more -
Young peoples health charity steps forward to claim top accolade and 35,000
Tower Hamlets-based charity, Step Forward, has beaten more than 400 organisations from around the UK to be crowned the overall winner of this year’s GlaxoSmithKline (GSK) ...
Read more -
pharmaceutical industry and university create manchester collaborative centre for inflammation research
GlaxoSmithKline (GSK), The University of Manchester, and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research (MCCIR), a uniq...
Read more -
GSK Q1 performance demonstrates continued progress with delivery of underlying sales growth, cash generation and pipeline visibility
Reported sales -10%; underlying sales* +4% EPS before major restructuring* 32.2p (+9%); dividend 16p (+7%)
Read more -
Regulatory update – GSK and Valeant respond to FDA on ezogabine
GSK and Valeant Pharmaceuticals International, Inc. submitted on 15 April 2011 the response to the U.S. FDA Complete Response letter received on 30 November 2010 for the NDA for...
Read more -
GSK welcomes key agreement to support global preparedness against pandemic influenza
GlaxoSmithKline (GSK) welcomes the agreement reached at the Open Ended Working Group (OEWG) coordinated by the World Health Organisation (WHO) on a Framework to support global p...
Read more -
GSK European regulatory update on Pandemrix™
GlaxoSmithKline (GSK) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended changes to the produ...
Read more -
Regulatory Update - Tyverb® lapatinib
GlaxoSmithKline plc (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Tyverb (lapatinib) in comb...
Read more -
GlaxoSmithKline announces non-core OTC products to be divested
GSK today identified the non-core OTC brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands...
Read more -
Unique research alliance expands collaboration opportunities at state-of-the-art medical imaging centre
The UK research community will soon have access to world-class medical imaging facilities in London with the signing of an agreement today between an alliance of leading London-...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
